

**Supplemental Table 4. Treatment-related adverse events of 30 RIS patients treated with chemotherapy plus anti-PD-1 antibody.**

Adverse Events	All grade	Grade $\geq$ 3	n (%)			
			Grade 1	Grade 2	Grade 3	Grade 4/5
Leukopenia	16 (53.3%)	3 (10.0%)	7	6	3	0
Neutropenia	6 (20.0%)	3 (10.0%)	2	1	3	0
Anemia	26 (86.7%)	5 (16.7%)	12	9	5	0
Thrombocytopenia	3 (10.0%)	1 (3.3%)	2	0	1	0
AST increased	3 (10.0%)	0	3	0	0	0
ALT increased	3 (10.0%)	0	1	2	0	0
Hyperlipidemia	7 (23.3%)	0	7	0	0	0
Hyperuricemia	3 (10.0%)	0	2	1	0	0
Hypoalbuminemia	9 (30.0%)	0	6	3	0	0
Proteinuria	3 (10.0%)	0	3	0	0	0
hematuresis	3 (10.0%)	0	3	0	0	0
<b>irAE</b>						
Hypothyroidism	7 (23.3%)	0	5	2	0	0
Hyperthyroidism	1 (3.3%)	0	0	1	0	0
Pneumonia	0	0	0	0	0	0
Myocardial enzyme increased	1 (3.3%)	0	0	1	0	0

No patients had any adverse events of Grade 4/5.

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; irAE, immune-related adverse event.